Abstract:Highlights • Intracellular ROS kinetics dictates antigen-presenting mode. • Sustained TLR2 activation triggers intracellular ROS kinetics required for cross-presentation. • A scaffold vaccine enabling "retention-and-release" for sustained TLR2 activation in DCs promotes cross-presentation. • The scaffold vaccine induces robust, CD8 + T cells-mediated anti-tumor immune responses in Apc min/+ transgenic mice. Cancer vaccination holds great promise for cancer treatment, but its effectiveness is hindered by suboptimal activation of CD8 + cytotoxic T lymphocytes, which are potent effectors to mediate anti-tumor immune responses. A possible solution is to switch antigen-presenting cells to present tumor antigens via the major histocompatibility complex class I (MHC-I) to CD8 + T cells – a process known as cross-presentation. To achieve this goal, we develop a three-dimensional (3D) scaffold vaccine to promote antigen cross-presentation by persisted toll-like receptor-2 (TLR2) activation after one injection. This vaccine comprises polysaccharide frameworks that "hook" TLR2 agonist (acGM) via tunable hydrophobic interactions and forms a 3D macroporous scaffold via click chemistry upon subcutaneous injection. Its retention-and-release of acGM enables sustained TLR2 activation in abundantly recruited dendritic cells in situ , inducing intracellular production of reactive oxygen species (ROS) in optimal kinetics that crucially promotes efficient antigen cross-presentation. The scaffold loaded with model antigen ovalbumin (OVA) or tumor specific antigen can generate potent immune responses against lung metastasis in B16-OVA-innoculated wild-type mice or spontaneous colorectal cancer in transgenic Apc Min/+ mice, respectively. Notably, it requires neither additional adjuvants nor external stimulation to function and can be adjusted to accommodate different antigens. The developed scaffold vaccine may represent a new, competent tool for next-generation personalized cancer vaccination. Graphical abstract A scaffold vaccine that promotes antigen cross-presentation to trigger CD8 + T cell-mediated anti-tumor immune responses . In this study, we discover that the kinetics of intracellular ROS, unexpectedly, dictates the mode of antigen presentation. Persistent production in moderate dose promotes antigen cross-presentation. To create optimal intracellular ROS kinetics for lysosomal disruption and antigen escape, we design a 3D injectable scaffold for the "retention-and-release" of a TLR2 agonist glycan upon subcutaneous implantation. Installation of tunable hydrophobic interactions between the scaffold and the "hooked" agonist enables sustained TLR activation in the abundantly recruited DCs in situ , which triggers consequently efficient cross-presentation of tumor antigens. The efficacy of this novel scaffold vaccine is subsequently undergoing comprehensive evaluations in both wild-type and transgenic mice against localized, metastatic, and spontaneous tumors. Download : Download high-res image (369KB) Download : Download full-size image

Manganese-based Microcrystals Equipped with Ythdf1-targeted Biomimetic Nanovaccines for Reinforced Dendritic Cell Spatiotemporal Orchestration

Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy

Synergistic Glutathione Depletion and STING Activation to Potentiate Dendritic Cell Maturation and Cancer Vaccine Efficacy

Manganese-mineralized cancer cells as immunogenic cancer vaccines for tumor immunotherapy

Orchestrated Cytosolic Delivery of Antigen and Adjuvant by Manganese Ion-Coordinated Nanovaccine for Enhanced Cancer Immunotherapy.

Enhancing Dendritic Cell Activation Through Manganese-Coated Nanovaccine Targeting the cGAS-STING Pathway

Ovalbumin-loaded Paramagnetic Nano-Triangles for Enhanced Dendritic Cell Stimulation, T1-MR Imaging, and Antitumor Immunity

Immunogenic Material Vaccine for Cancer Immunotherapy by Structure‐dependent Immune Cell Trafficking and Modulation

Biomineralization-inspired synthesis of autologous cancer vaccines for personalized metallo-immunotherapy

Tumor microenvironment-responsive manganese-based nano-modulator activate the cGAS-STING pathway to enhance innate immune system response

Multi-Metallic Nanosheets Reshaping Immunosuppressive Tumor Microenvironment through Augmenting cGAS-STING Innate Activation and Adaptive Immune Responses for Cancer Immunotherapy

2D Differential Metallic Immunopotentiators Drive High Diversity and Capability of Antigen-specific Immunity Against Tumor

Metal-Organic Framework-Based Nanovaccine for Relieving Immunosuppressive Tumors Via Hindering Efferocytosis of Macrophages and Promoting Pyroptosis and Cuproptosis of Cancer Cells.

A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation

A Mn Al double adjuvant nanovaccine to induce strong humoral and cellular immune responses

Cytosolic Delivery of Thiolated Mn‐cGAMP Nanovaccine to Enhance the Antitumor Immune Responses

STING Nanoagonist Boosts Antitumor Immunity of Therapeutic DNA Vaccines

Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapy

Direct Presentation of Tumor‐Associated Antigens to Induce Adaptive Immunity by Personalized Dendritic Cell‐Mimicking Nanovaccines

Manganese-phenolic nanoadjuvant combines sonodynamic therapy with cGAS-STING activation for enhanced cancer immunotherapy

Manganese-coordinated nanoparticle with high drug-loading capacity and synergistic photo-/immuno-therapy for cancer treatments